Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | PHGDH | O43175 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13895693 | 0.87 | MCL1 (0.58) | MCL1PHGDHTP53RXFP1GPR35 | |
| SCHEMBL13881405 | 0.87 | KDM4E (0.46) | MCL1PHGDHTP53RXFP1GPR35 | |
| SCHEMBL13895694 | 0.86 | SLC9A1 (0.42) | MCL1PHGDHTP53RXFP1GPR35 | |
| SCHEMBL10084914 | 0.77 | MCL1 (0.57) | MCL1GPR35 | |
| SCHEMBL17324790 | 0.74 | KDM4E (0.59) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL30790917 | 0.74 | HSD17B10 (0.62) | MCL1PHGDHGPR35KDM4EALDH1A1 | |
| SCHEMBL9613270 | 0.74 | HSD17B10 (0.62) | MCL1PHGDHGPR35KDM4EALDH1A1 | |
| SCHEMBL401039 | 0.74 | MCL1 (0.73) | MCL1PHGDHSLC9A1MAPT | |
| SCHEMBL23171258 | 0.74 | LMNA (0.39) | RXFP1EIF4A3TYRHTR7KDM4E | |
| SCHEMBL13677503 | 0.74 | HTR7 (0.38) | PHGDHEIF4A3TYRHTR7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629141-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-01-14 | — | — | US | disclosed |
| US-20120289494-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | SANOFI (FR) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289494-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | MCL1 304/4885PHGDH 2561/4885TP53 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.